Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.51% | 49.58% | 47.44% | 44.71% | 45.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.51% | 49.58% | 47.44% | 44.71% | 45.41% |
| Cost of Revenue | 40.31% | 43.01% | 38.30% | 31.30% | 29.25% |
| Gross Profit | 46.57% | 50.96% | 49.48% | 47.79% | 49.23% |
| SG&A Expenses | 20.63% | 25.93% | 28.83% | 32.88% | 40.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.26% | 30.06% | 30.64% | 27.88% | 28.54% |
| Operating Income | 68.89% | 76.88% | 72.63% | 72.36% | 74.83% |
| Income Before Tax | 54.50% | 99.27% | 128.87% | 102.94% | 121.71% |
| Income Tax Expenses | 75.72% | 125.01% | 134.52% | 143.61% | 129.78% |
| Earnings from Continuing Operations | 49.79% | 93.56% | 127.60% | 94.91% | 119.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.79% | 93.56% | 127.60% | 94.91% | 119.99% |
| EBIT | 68.89% | 76.88% | 72.63% | 72.36% | 74.83% |
| EBITDA | 65.21% | 71.69% | 67.43% | 66.78% | 68.66% |
| EPS Basic | 50.59% | 94.57% | 128.76% | 95.79% | 120.65% |
| Normalized Basic EPS | 72.43% | 81.59% | 76.35% | 73.99% | 80.18% |
| EPS Diluted | 50.72% | 94.75% | 129.01% | 95.96% | 121.03% |
| Normalized Diluted EPS | 72.50% | 81.72% | 76.52% | 74.19% | 80.43% |
| Average Basic Shares Outstanding | -0.55% | -0.53% | -0.46% | -0.40% | -0.28% |
| Average Diluted Shares Outstanding | -0.59% | -0.61% | -0.57% | -0.52% | -0.40% |
| Dividend Per Share | 15.34% | 15.36% | 15.37% | 15.38% | 15.31% |
| Payout Ratio | -0.23% | -0.41% | -0.49% | -0.41% | -0.48% |